Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Pricing Strategies Pricing Debate Business Strategies

Sanofi US Net Prices Declined In 2021, But Less So Than In Prior Years

  • News

Executive Summary

Sanofi's US net drug prices declined 1.3% in 2021, the smallest decline in six years of publicly disclosing aggregate list and net price information.

You may also be interested in...



Sanofi Paid $14.6bn In Rebates In 2020; Net Prices Were Down

The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.

Agios CEO Fouse On Building A Sustainable Business Model

In the midst of another restructuring, the company is transitioning from a drug discovery company to a more externally focused R&D model; CEO Jackie Fouse talked to Scrip about the changes at Agios.

Seagen CEO Search Under Way As Longtime Leader Siegall Resigns In Scandal

Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.

Table

View full table

Topics

Related Companies

Tags:
Pricing Strategies Pricing Debate Business Strategies
UsernamePublicRestriction

Register

SC145978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By